Ensysce Biosciences, Inc. (ENSC) stock
ENSCNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.38−0.03 (-6.28%)
Close on Nov 17, 2026Market cap $7.47MP/E –Yield –
Ensysce Biosciences operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Ensysce Biosciences's operating cash flow for the twelve months ending Jun 30, 2026 was -$8.86M. For fiscal 2025 it was -$7.81M. The highest annual figure on record is -$1.24M in fiscal 2018.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$7.81M | – |
| FY2024 | Dec 31, 2024 | -$7.50M | – |
| FY2023 | Dec 31, 2023 | -$10.78M | – |
| FY2022 | Dec 31, 2022 | -$17.89M | – |
| FY2021 | Dec 31, 2021 | -$8.24M | – |
| FY2020 | Dec 31, 2020 | -$1.25M | – |
| FY2019 | Dec 31, 2019 | -$1.42M | – |
| FY2018 | Dec 31, 2018 | -$1.24M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$1.96M | – |
| Q1 FY2026 | Mar 31, 2026 | -$3.50M | – |
| Q4 FY2025 | Dec 31, 2025 | -$1.53M | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.87M | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.71M | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.71M | – |
| Q4 FY2024 | Dec 31, 2024 | -$764.09K | – |
| Q3 FY2024 | Sep 30, 2024 | -$1.02M | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.31M | – |
| Q1 FY2024 | Mar 31, 2024 | -$3.41M | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.80M | – |
| Q3 FY2023 | Sep 30, 2023 | -$2.26M | – |
| Q2 FY2023 | Jun 30, 2023 | -$3.11M | – |
| Q1 FY2023 | Mar 31, 2023 | -$3.61M | – |
| Q4 FY2022 | Dec 31, 2022 | -$3.30M | – |
| Q3 FY2022 | Sep 30, 2022 | -$6.71M | – |
| Q2 FY2022 | Jun 30, 2022 | -$4.44M | – |
| Q1 FY2022 | Mar 31, 2022 | -$3.44M | – |
| Q4 FY2021 | Dec 31, 2021 | -$3.77M | – |
| Q3 FY2021 | Sep 30, 2021 | -$3.82M | – |
| Q2 FY2021 | Jun 30, 2021 | -$132.31K | – |
| Q1 FY2021 | Mar 31, 2021 | -$517.15K | – |
| Q4 FY2020 | Dec 31, 2020 | -$533.86K | – |
| Q3 FY2020 | Sep 30, 2020 | -$152.91K | – |
| Q2 FY2020 | Jun 30, 2020 | -$326.19K | – |
| Q1 FY2020 | Mar 31, 2020 | -$234.39K | – |
| Q4 FY2019 | Dec 31, 2019 | -$425.76K | – |
| Q3 FY2019 | Sep 30, 2019 | -$272.23K | – |
| Q2 FY2019 | Jun 30, 2019 | -$432.44K | – |
| Q1 FY2019 | Mar 31, 2019 | -$294.37K | – |
| Q4 FY2018 | Dec 31, 2018 | -$458.64K | – |
| Q3 FY2018 | Sep 30, 2018 | -$110.65K | – |
| Q2 FY2018 | Jun 30, 2018 | -$452.14K | – |
| Q1 FY2018 | Mar 31, 2018 | -$216.83K | – |
See a number that looks wrong?